Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers
Nat Cancer
.
2024 Jul;5(7):1130.
doi: 10.1038/s43018-024-00797-y.
Authors
Emilie A Chapeau
1
,
Laurent Sansregret
2
,
Giorgio G Galli
2
,
Patrick Chène
2
,
Markus Wartmann
2
,
Thanos P Mourikis
2
,
Patricia Jaaks
2
,
Sabrina Baltschukat
2
,
Ines A M Barbosa
2
,
Daniel Bauer
2
,
Saskia M Brachmann
2
,
Clara Delaunay
2
,
Claire Estadieu
2
,
Jason E Faris
3
,
Pascal Furet
2
,
Stefanie Harlfinger
2
4
,
Andreas Hueber
2
,
Eloísa Jiménez Núñez
2
,
David P Kodack
3
,
Emeline Mandon
2
,
Typhaine Martin
2
,
Yannick Mesrouze
2
,
Vincent Romanet
2
,
Clemens Scheufler
2
,
Holger Sellner
2
,
Christelle Stamm
2
,
Dario Sterker
2
,
Luca Tordella
2
,
Francesco Hofmann
2
5
,
Nicolas Soldermann
2
,
Tobias Schmelzle
6
Affiliations
1
Novartis BioMedical Research, Basel, Switzerland. emilie.chapeau@novartis.com.
2
Novartis BioMedical Research, Basel, Switzerland.
3
Novartis BioMedical Research, Cambridge, MA, USA.
4
AstraZeneca, Oncology R&D, Cambridge, UK.
5
Pierre Fabre Group, R&D Medical Care, Toulouse, France.
6
Novartis BioMedical Research, Basel, Switzerland. tobias.schmelzle@novartis.com.
PMID:
38886525
PMCID:
PMC11286518
DOI:
10.1038/s43018-024-00797-y
No abstract available
Publication types
Published Erratum